{
    "organizations": [],
    "uuid": "d1737d4057fcf9735c9920ab8a7ca28132a14f44",
    "author": "Peter Loftus",
    "url": "https://www.wsj.com/articles/drug-firm-spark-therapeutics-will-charge-850-000-for-vision-loss-gene-therapy-1514986201",
    "ord_in_thread": 0,
    "title": "Drug Firm Spark Therapeutics Will Charge $850,000 for Vision-Loss Gene Therapy",
    "locations": [],
    "highlightText": "",
    "language": "english",
    "persons": [],
    "text": "Spark Therapeutics Inc. said it would charge $850,000 a patient for a pioneering new treatment for a hereditary form of vision loss—below the $1 million price tag the company had considered, but still a milestone for ever-rising drug prices in the U.S.\n\nTo address concerns about the cost of the drug, Luxturna, Spark said it is offering alternative payment arrangements to health insurers, including partial refunds if a patient’s vision doesn’t improve significantly after treatment. The company also is seeking U.S. government...  ",
    "published": "2018-01-03T15:30:00.000+02:00",
    "crawled": "2018-01-03T16:06:06.012+02:00",
    "highlightTitle": "",
    "preprocessed_text": [
        "spark",
        "therapeutic",
        "said",
        "would",
        "charge",
        "patient",
        "pioneering",
        "new",
        "treatment",
        "hereditary",
        "form",
        "vision",
        "million",
        "price",
        "tag",
        "company",
        "considered",
        "still",
        "milestone",
        "drug",
        "price",
        "address",
        "concern",
        "cost",
        "drug",
        "luxturna",
        "spark",
        "said",
        "offering",
        "alternative",
        "payment",
        "arrangement",
        "health",
        "insurer",
        "including",
        "partial",
        "refund",
        "patient",
        "vision",
        "improve",
        "significantly",
        "treatment",
        "company",
        "also",
        "seeking",
        "government"
    ]
}